Gastrointestinal Imaging

Which Imaging Study Is Best for Staging Newly Diagnosed Esophageal Cancer?

·
Which Imaging Study Is Best for Staging Newly Diagnosed Esophageal Cancer?

A 67-year-old patient with progressive dysphagia undergoes an esophagogastroduodenoscopy (EGD), and the biopsy returns positive for adenocarcinoma of the distal esophagus. As the referring gastroenterologist, your next critical step is to determine the extent of the disease before the case is presented to the multidisciplinary tumor board. Accurate pretreatment clinical staging is paramount, as it will dictate whether the patient is a candidate for surgery, neoadjuvant therapy, or definitive chemoradiation. This decision hinges on the initial imaging workup. This article provides a detailed workflow for this specific scenario: initial imaging for pretreatment clinical staging of newly diagnosed esophageal cancer. Based on the American College of Radiology (ACR) Appropriateness Criteria, a `CT chest and abdomen with IV contrast` is rated Usually Appropriate and serves as the foundational study for this workup.

Who Fits the Scenario of Initial Staging for Newly Diagnosed Esophageal Cancer?

This guidance applies specifically to patients with a new, histologically confirmed diagnosis of esophageal cancer, either adenocarcinoma or squamous cell carcinoma, who have not yet undergone any form of treatment. The primary goal is to establish the baseline clinical stage (TNM: Tumor, Node, Metastasis) to inform the initial therapeutic strategy.

It is crucial to distinguish this scenario from others that require different imaging approaches. This workflow does not apply to patients who are:

  • Currently undergoing treatment: Patients receiving chemotherapy or radiation therapy may require imaging to assess treatment response. This falls under the ACR variant for “Esophageal cancer. Imaging during treatment.”
  • In post-treatment surveillance: Asymptomatic patients who have completed their primary course of therapy and are being monitored for recurrence follow the “Posttreatment imaging. No suspected or known recurrence” guidelines.
  • Suspected of having a recurrence: Patients who have completed treatment and now present with new or worsening symptoms (like recurrent dysphagia, pain, or weight loss) require a workup guided by the “Posttreatment imaging. Suspected or known recurrence” criteria.

Applying the correct imaging strategy at the outset is essential for developing an effective and appropriate treatment plan.

What Are You Assessing with Initial Staging Imaging for Esophageal Cancer?

While the primary diagnosis of esophageal cancer is already confirmed by biopsy, the purpose of initial staging imaging is to answer three critical questions about the extent of the disease. The imaging findings directly inform the clinical stage, which is the most important factor in determining prognosis and treatment.

M-stage (Metastatic Disease): This is arguably the most important question to answer with the initial cross-sectional study. The presence of distant metastases (Stage IV disease) fundamentally changes the treatment goal from curative to palliative. CT is highly effective at surveying the most common sites of esophageal cancer metastasis, including the liver, lungs, adrenal glands, and distant (non-regional) lymph nodes.

N-stage (Nodal Involvement): The second key objective is to identify suspicious regional lymph nodes. For esophageal cancer, this includes nodes in the mediastinum and upper abdomen (e.g., celiac axis, gastrohepatic ligament). While CT relies on size criteria and morphology, which has limitations, it provides an excellent initial assessment of the nodal burden that helps guide subsequent steps like endoscopic ultrasound (EUS).

T-stage (Local Tumor Invasion): Imaging helps define the local extent of the primary tumor. This includes its relationship to adjacent critical structures like the aorta, tracheobronchial tree, and pericardium. Evidence of direct invasion into these structures (T4b disease) may render the tumor unresectable and alter the treatment plan towards non-surgical approaches. While CT provides this crucial information, it is less accurate than EUS for differentiating early T-stages within the esophageal wall.

Why Is CT of the Chest and Abdomen with IV Contrast Usually Appropriate for Initial Staging?

For the initial staging of a newly diagnosed esophageal cancer, the ACR panel rates `CT chest and abdomen with IV contrast` as Usually Appropriate. This recommendation is based on the modality’s wide availability, speed, and ability to provide a comprehensive anatomic survey to assess the T, N, and M stages in a single examination.

Intravenous (IV) contrast is non-negotiable in this setting. It is essential for opacifying blood vessels to assess for vascular invasion, evaluating solid organ parenchyma for metastases (especially in the liver and adrenal glands), and increasing the conspicuity of lymph nodes and the primary tumor itself. A non-contrast study is inadequate for cancer staging.

While CT is a cornerstone, it’s important to understand its role relative to other powerful imaging tools:

  • FDG-PET/CT skull base to mid-thigh is also rated Usually Appropriate. Positron Emission Tomography (PET) provides functional information about metabolic activity, making it highly sensitive for detecting metastatic disease in lymph nodes and distant sites that may be normal in size on CT. Many cancer centers incorporate PET/CT into the initial staging pathway, often after the initial CT or as a combined study. It is particularly valuable for clarifying equivocal findings on CT and detecting unexpected distant disease that would change management.
  • MRI chest and abdomen without and with IV contrast is rated May be appropriate. MRI is not a first-line tool for the overall staging of esophageal cancer. However, it excels as a problem-solving modality, particularly for characterizing an indeterminate liver lesion seen on CT. Its superior soft-tissue contrast can definitively diagnose a benign lesion like a hemangioma and avert the need for a biopsy.

The recommended CT study involves a significant radiation dose (ACR Relative Radiation Level ☢☢☢☢, 10-30 mSv), but this exposure is well-justified in the setting of a life-threatening malignancy where accurate staging is critical to patient outcomes.

Once you’ve decided on cross-sectional imaging, our protocol guide covers the technique, contrast, and reading principles for a comprehensive study: CT Chest/Abdomen/Pelvis with IV Contrast. Note that while the core ACR recommendation is for the chest and abdomen, many institutional protocols extend coverage to the pelvis to screen for osseous or other distant metastases.

What Is the Downstream Workflow After the Initial Staging CT?

The results of the initial staging CT create critical branch points in the patient’s management pathway. The report should be interpreted in the context of the overall clinical picture to guide the next steps, which are typically discussed in a multidisciplinary tumor board.

If the CT shows localized or locoregional disease only: If there is no evidence of distant metastases (M0 disease), the patient is considered a candidate for curative-intent therapy. The next step is typically an Endoscopic Ultrasound (EUS) with Fine-Needle Aspiration (FNA). EUS provides superior resolution of the esophageal wall and surrounding lymph nodes, offering the most accurate local T and N staging. This detailed local staging is essential for distinguishing patients who can proceed directly to surgery from those who would benefit from neoadjuvant chemotherapy and/or radiation first.

If the CT shows definitive distant metastatic disease (M1): The identification of clear metastases in the liver, lungs, or other distant sites classifies the patient as having Stage IV disease. In this case, the treatment intent shifts from curative to palliative. The patient is typically referred to medical oncology to discuss systemic therapy (chemotherapy, targeted therapy, or immunotherapy). EUS may not be necessary, as local staging details will not change the systemic nature of the treatment plan.

If the CT is indeterminate: Sometimes, the CT will reveal ambiguous findings, such as a single, small, non-specific liver lesion, a borderline-sized lymph node, or a subtle lung nodule. This is a common scenario where FDG-PET/CT is invaluable. A PET-avid (metabolically active) lesion is highly suspicious for metastasis and may prompt a biopsy for confirmation. A PET-negative finding significantly lowers the likelihood of malignancy and may allow the patient to proceed with a curative-intent treatment plan.

Common Pitfalls in Initial Esophageal Cancer Staging (and When to Escalate)

Navigating the initial staging workup requires attention to detail to avoid common errors that can lead to incorrect staging and suboptimal treatment decisions.

  • Pitfall: Ordering a non-contrast CT. A CT of the chest and abdomen performed without IV contrast is insufficient for staging esophageal cancer. It severely limits the evaluation of solid organs for metastases, obscures the relationship of the tumor to major blood vessels, and poorly delineates lymph nodes.
  • Pitfall: Relying solely on CT for T-staging. CT cannot reliably differentiate early T-stages (e.g., T1 vs. T2 vs. T3). For any patient with non-metastatic disease being considered for curative therapy, EUS is mandatory for accurate local staging.
  • Pitfall: Not clarifying indeterminate findings. An ambiguous finding on the initial CT should not be ignored. Failing to resolve an indeterminate liver or lung lesion with PET/CT or another modality could lead to under-staging a patient who actually has metastatic disease.

When imaging findings are complex, staging is ambiguous, or the patient has significant comorbidities, the case must be escalated for discussion at a multidisciplinary tumor board. This collaborative review by surgeons, oncologists, radiologists, and other specialists is the standard of care for ensuring the patient receives the most appropriate, evidence-based treatment plan.

Related ACR Topics and Tools

This article focuses on a single clinical scenario. For a comprehensive overview of all imaging variants related to this condition, from staging to post-treatment follow-up, please consult the parent topic guide. You can also use the tools below to explore related criteria, protocols, and radiation dose information.

Frequently Asked Questions

Why is FDG-PET/CT also rated ‘Usually Appropriate’? When should I choose it over a standard CT?

FDG-PET/CT is also ‘Usually Appropriate’ because it adds valuable functional information to the anatomic detail provided by CT. It is more sensitive for detecting small metastatic deposits in lymph nodes and distant organs. Many institutions use it routinely in initial staging. A common workflow is to start with a diagnostic-quality contrast-enhanced CT. If that shows no metastatic disease, a PET/CT is often performed to confirm the absence of distant disease before proceeding with curative-intent therapy. If the CT is equivocal, PET/CT is the ideal next step to clarify ambiguous findings.

The ACR recommendation is for CT Chest/Abdomen. Should I order a CT of the pelvis as well?

This is a common point of discussion. The ACR rates ‘CT chest abdomen pelvis with IV contrast’ as ‘May be appropriate (Disagreement)’. The primary landing sites for esophageal cancer metastases are in the chest and abdomen. However, spread to pelvic bones or nodes can occur. Many cancer centers adopt a routine protocol of CT chest, abdomen, and pelvis for most oncologic staging to provide a complete baseline. The decision often depends on institutional protocol and the specific clinical picture, but extending coverage to the pelvis is a very reasonable practice.

What is the role of endoscopic ultrasound (EUS)? Does the CT replace it?

No, CT does not replace EUS. They are complementary studies. CT provides a wide-field-of-view assessment of the entire chest and abdomen to look for distant disease (M-staging) and bulky nodal disease (N-staging). EUS provides a highly detailed, localized view of the tumor’s depth of invasion into the esophageal wall (T-staging) and allows for biopsy of adjacent lymph nodes (N-staging). For any patient with non-metastatic disease on CT, EUS is essential for accurate local staging to guide therapy.

My patient has severe renal dysfunction. How should I approach staging imaging?

This complicates staging, as IV iodinated contrast for CT is often contraindicated in severe chronic kidney disease. One option is a non-contrast CT of the chest combined with a contrast-enhanced MRI of the abdomen using a gadolinium-based agent (if GFR allows and the agent is low-risk for NSF). FDG-PET/CT is another excellent option, as the PET component does not require iodinated contrast, and the CT portion can be performed without contrast for localization and still provide staging information for the lungs and bones, though organ evaluation is limited. Consultation with a radiologist is highly recommended to determine the best alternative imaging strategy.

Is a barium esophagram (upper GI series) useful for initial staging?

A barium esophagram is rated ‘Usually not appropriate’ for staging. While it can be useful for defining the length of a stricture and assessing for a tracheoesophageal fistula, it provides no information about tumor invasion, lymph nodes, or distant metastases. Its role is largely limited to evaluating swallowing function or for radiation therapy planning, not for the initial TNM staging workup.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026